Equity
€71,797 from €256,230 in 2022
Equity fell by 72% in 3 years.
OAMM
Lifetime
13 annual accounts with figures on one time axispeak €2.1m (2024)
€1.9m▼ 6.3%
lowest -€232,245 (2013)
€456,820▼ 40.6%
peak €256,230 (2022)
€71,797▼ 40.2%
€1.5m▲ 14.9%
peak 17.4 FTE (2025)
17.4 FTE▲ 16.0%
Board6 names since 2020
4 directorsCathérine Deghislage and 3 others
Owners2 names in the annual accounts
Documentsfilings and deeds
30-06-202631 days before the deadline
2025financial year
Result from €768,588 to €456,820Staff from 15 FTE to 17.4 FTE4 directors reappointed 18-08Dividend €225,000Equity from €119,977 to €71,7971 establishment registered
Key points
from the 2025 annual accountsResult
€456,820 ▼ 40.6%
The result fell in 2025 from €768,588 to €456,820.
Debts
€1.5m 95% of the balance sheet
Financial debts 0%Suppliers 27%Taxes and wages 9%Other 64%
Of this, €1.5m falls due within a year.
Staff
21 employees on 31-12-2025
In 2025, 7 people joined and 3 left.
Filings
13 annual accounts since 2013
Three of the last ten came late. The 2016 accounts came latest: 31 days after the end of the period.
Position in the sector
4.6%
Lower solvency than 89% of companies in human health. Sector median 57.8% · 784 companies.
Checked score
88
Excellent
Financially stronger than 27% of small companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 1,080 companies (NACE 86, small).
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%lowest value
01-2025: 0.1%● unchanged vs 12-2024lowest value
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.1%● unchanged vs 06-2025
08-2025: 0.1%● unchanged vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026highest value
05-2026: 0.1%● unchanged vs 04-2026highest value
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.1%● unchanged vs 06-2026
08-2026: 0.1%● unchanged vs 07-2026
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Financial strengthWeak
Score breakdown
raises risk
Equity €71,797 (4.6% of total assets)
lowers risk
Sector: Human health activities (NACE 86)
Figures for financial year 2025 (filed on 30-06-2026)
Profit of €456,820 (financial year 2025)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, small). It does better than 5% of them on solvency, 1% on liquidity, 98% on profitability and 3% on growth.
The bankruptcy probability was computed on 07-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 536 companies had the same profile as OAMM has now. Each dot stands for 2 companies, two years later.
95.9%
were still trading
3.4%
stopped another way
0.7%
went bankrupt
That fits the bankruptcy probability of OAMM itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 536 companies, not a prediction for OAMM. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €6,000 on 30-day terms is acceptable
Liquidity is insufficient, with a current ratio of 0.38 (0.43 in 2024), below 1. Short-term debt is 95.4% and cash 7.1% of total assets. 95.4% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 11% of 784 sector peers (2025).
NBB · sector comparisonPosition among 784 sector peers
Solvency
better than 11%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-06-2026, 31 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
31 days early
2024
30 days early
2023
9 days early
2022
14 days early
2021
16 days early
2020
8 days early
2019
31 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 11 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 15 July (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
08-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Amendment of the articles
Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0847840871
New establishment in Diepenbeek
Nieuwstraat 173
4 directors reappointed
Cathérine Deghislage, Huib Lodewijks, Eqiris and Signifeye · Permanent representatives: Heintz Bernard and Kathleen Moons · General meeting of 27-06-2025 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| OAMM Maasmechelen | €1.6m | €1.9m | 4.6% | 17.4 |
| Maison médicale Saint Léonard Centre de Santé intégré asbl Liège | €1.9m | €2.0m | 70.2% | 22.6 |
| DERMPAT Ghent | €1.2m | €1.1m | 51.7% | 11.4 |
| Dermatologie Kempenland Beerse | €1.9m | €1.0m | 1.3% | 10.8 |
| BELGO-INTERNATIONAL RESEARCH APPLICATIONS en DEVELOPMENT Genk | €3.0m | €2.4m | 9.0% | 22.3 |
| Praktijk Dr. Feriduni Hasselt | €3.8m | €1.4m | 32.7% | 10.4 |
| DR.DE BAERE K., ANESTHESIST - DR. VAN AKEN E., OOGARTS Destelbergen | €2.1m | €2.4m | 4.6% | - |
These companies have the same main activity as OAMM: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €1.2m and €3.8m, founded between 1996 and 2013.
Official details
Source: KBO- Status
- Active since 31-07-2012Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Joint committee
- 330.04Health institutions and services · annual accounts 2025
- Establishment units
- 2.212.074.8053630 Maasmechelen, since 03-08-2012
- 2.214.786.9443630 Maasmechelen, since 01-10-2012and 2 others
- Financial year end
- 31 December
- Peppol
- Reachable since 15-12-2025
Annual accounts 2025
- ≈ €1.7mestimated
- €1.6m▲ 10.2%
- Employeeson 31-12-2025
- 21▲ 23.5%
- Filing
- Filed on 30-06-2026, 31 days before the end of the filing period
Insights on OAMM
OAMM has existed since 2012. The gross margin grew from €779,977 in 2013 to €1.9m in 2025 and staff from 10.6 to 17.4 full-time equivalents.
EQIRIS holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about OAMM
- What is the company number of OAMM?
- The company number of OAMM is 0847.840.871. The VAT number is the same number with BE in front: BE 0847.840.871.
- Where is OAMM based?
- The registered office is at Olympialaan 20, 3630 Maasmechelen.Company details
- What does OAMM do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of OAMM?
- OAMM is a public limited company (NV).
- When was OAMM founded?
- OAMM was founded on 31-07-2012.
- Is OAMM still active?
- Yes, OAMM is an active enterprise in the KBO register.
- How many employees does OAMM have?
- OAMM had an average of 17.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does OAMM fall under?
- In its 2025 annual accounts, OAMM states joint committee 330.04 (Health institutions and services).
- What is the turnover of OAMM?
- The turnover in financial year 2025 is ≈ €1.7m. This figure is estimated from the gross margin of €1.9m and 63 comparable companies (NACE 86). It probably lies between €1.6m and €2.5m.
- Is OAMM profitable?
- In financial year 2025, OAMM made a profit of €456,820.
- Where can I find the annual accounts of OAMM?
- OAMM filed 13 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of OAMM due?
- OAMM must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See the other companies in the same group.Signifeye · 12 companies
See how customers, suppliers and banks see your own company and what to improve first.